Advertisement

help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

The Oncologist, Vol. 12, No. 11, 1336-1343, November 2007; doi:10.1634/theoncologist.12-11-1336
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berg, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berg, S. L.

Pediatric Oncology

Ethical Challenges in Cancer Research in Children

Stacey L. Berg

Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA

Key Words. Ethics • Pediatrics • Cancer • Clinical trials

Correspondence: Stacey L. Berg, M.D., Texas Children's Cancer Center, 6621 Fannin Street, MC3-3320, Houston, Texas 77030, USA. Telephone: 832-824-4588; Fax: 832-825-4039; e-mail: sberg{at}txccc.org

Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

Clinical research has led to great advances in cancer therapy for children, and a greater proportion of children than adults with cancer participate in clinical trials. Despite this success, there remain important ethical challenges in conducting this research. There are challenges in obtaining informed consent and assent when children are research subjects; challenges arising from study design issues in phase III, II, or I clinical trials; and challenges related to the development of new classes of drugs, especially molecularly targeted therapies. It is important for researchers and clinicians to understand these challenges so that progress in cancer treatment is achieved in a sound ethical and regulatory fashion.







HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2007 by AlphaMed Press.
Advertisement